Revolution Medicines (RVMD) Net Income (2019 - 2026)

Revolution Medicines' Net Income history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• In Q1 2026, Net Income fell 112.64% year-over-year to -$453.8 million; the TTM figure through Mar 2026 stood at -$240.4 million (up 65.53% YoY), while the FY2024 annual figure was -$600.0 million, down 36.31% from the prior year.
• Net Income was -$453.8 million for Q1 2026 at Revolution Medicines, down from $766.4 million in the prior quarter.
• In the past five years, Net Income ranged from a high of $766.4 million in Q4 2025 to a low of -$453.8 million in Q1 2026.
• Historically, Net Income has averaged -$102.5 million across 5 years, with a median of -$116.0 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Net Income plunged 192.58% in 2023, then jumped 494.0% in 2025.
• A 5-year view of Net Income shows it stood at -$56.5 million in 2022, then sank by 192.58% to -$165.4 million in 2023, then dropped by 17.62% to -$194.5 million in 2024, then surged by 494.0% to $766.4 million in 2025, then tumbled by 159.21% to -$453.8 million in 2026.
• The last three Net Income figures came in at -$453.8 million (Q1 2026), $766.4 million (Q4 2025), and -$305.2 million (Q3 2025), per Business Quant data.